Are Wall Street Analysts Bullish on McKesson Stock?

Core Insights - McKesson Corporation, based in Irving, Texas, is one of America's oldest businesses with a market capitalization of approximately $105.6 billion, focusing on pharmaceutical distribution, medical supply delivery, and technology solutions [1] Market Performance - Over the past 52 weeks, McKesson's stock has increased by 39.8% and by 51% year-to-date, significantly outperforming the S&P 500 Index, which gained 12.3% and 12.5% in the same periods [2] - The stock has also outperformed the S&P 500 Healthcare Sector SPDR, which saw a 7.5% increase over the past 52 weeks and a 10.9% rise year-to-date [3] Financial Results - For the second quarter of fiscal year 2026, McKesson reported a revenue increase of 10.1% year-over-year, reaching $103.2 billion, aligning with analyst expectations, driven by stronger prescription volumes and broader distribution of oncology and multispecialty products [4] - Earnings per share (EPS) surged 377% annually to $8.92, surpassing expectations, and the management has raised its adjusted EPS outlook for fiscal year 2026 to a range of $38.35 to $38.85 [5] Analyst Outlook - Analysts forecast a 17% EPS growth to $38.66 on a diluted basis for the fiscal year ending in March 2026, with McKesson exceeding analyst expectations for three consecutive quarters [6] - The consensus rating among 16 analysts covering McKesson is "Strong Buy," with 13 "Strong Buy" calls and three "Hold" recommendations [6] - Following the Q2 results, Baird analyst Eric Coldwell raised McKesson's price target to $927 from $873, maintaining an "Outperform" stance, indicating confidence in the company's momentum [7]